Three monocyte‐related determinants of atherosclerosis in haemodialysis

Jacobson, Stefan H.; Thylén, Pia; Lundahl, Joachim

doi:10.1093/ndt/15.9.1414

Cited by 20 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The plasma concentration of MCP-1 was increased significantly in PD and HD patients, and the plasma concentration of soluble TGF-␤ was increased in HD patients only, confirming previous reports (33)(34)(35)(36). MCP-1 is associated with macrophage infiltration into the peritoneal cavity of PD patients and correlates with soluble adhesion molecule expression in HD (33,37).…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Profound Mishandling of Protein Glycation Degradation Products in Uremia and Dialysis

Agalou

Ahmed

Babaei‐Jadidi

et al. 2005

Journal of the American Society of Nephrology

129

135

View full text Add to dashboard Cite

The aim of this study was to define the severe deficits of protein glycation adduct clearance in chronic renal failure and elimination in peritoneal dialysis (PD) and hemodialysis (HD) therapy using a liquid chromatography-triple quadrupole mass spectrometric detection method. Physiologic proteolysis of proteins damaged by glycation, oxidation, and nitration forms protein glycation, oxidation, and nitration free adducts that are released into plasma for urinary excretion. Inefficient elimination of these free adducts in uremia may lead to their accumulation. Patients with mild uremic chronic renal failure had plasma glycation free adduct concentrations increased up to five-fold associated with a decline in renal clearance. In patients with ESRD, plasma glycation free adducts were increased up to 18-fold on PD and up to 40-fold on HD. Glycation free adduct concentrations in peritoneal dialysate increased over 2-to 12-h dwell time, exceeding the plasma levels markedly. Plasma glycation free adducts equilibrated rapidly with dialysate of HD patients, with both plasma and dialysate concentrations decreasing during a 4-h dialysis session. It is concluded that there are severe deficits of protein glycation free adduct clearance in chronic renal failure and in ESRD on PD and HD therapy.

show abstract

Section: Discussionsupporting

confidence: 90%

“…MCP-1 is associated with macrophage infiltration into the peritoneal cavity of PD patients and correlates with soluble adhesion molecule expression in HD (33,37). TGF-␤ is a key mediator of renal fibrosis in progressive renal failure and ESRD.…”

Section: Discussionmentioning

confidence: 99%

Profound Mishandling of Protein Glycation Degradation Products in Uremia and Dialysis

Agalou

Ahmed

Babaei‐Jadidi

et al. 2005

Journal of the American Society of Nephrology

129

135

View full text Add to dashboard Cite

show abstract

“…13 However, there have been few studies of the relationship between the severity of human atherosclerosis and the serum concentration of MCP-1 in HD patients. 13,14 High-resolution ultrasound imaging is now a reliable means of directly examining and quantifying pre-clinical Circulation Journal Vol. 68, July 2004 atherosclerotic lesions in peripheral arteries.…”

mentioning

confidence: 99%

“…[4][5][6][7][8][9][10][11][12] In the clinical setting, it has been reported that the plasma concentrations of several cytokines and chemokines, including MCP-1, increased during long-term HD treatment. 13 However, there have been few studies of the relationship between the severity of human atherosclerosis and the serum concentration of MCP-1 in HD patients. 13,14 High-resolution ultrasound imaging is now a reliable means of directly examining and quantifying pre-clinical Circulation Journal Vol.…”

mentioning

confidence: 99%

Significance of the Level of Monocyte Chemoattractant Protein-1 in Human Atherosclerosis-Assessment in Chronic Hemodialysis Patients-

Kusano

Nakamura

Kusano³

et al. 2004

Circ J

View full text Add to dashboard Cite

he rates of cardiovascular or cerebrovascular mortality related to accelerated atherosclerosis are high in patients undergoing chronic hemodialysis (HD) treatment. 1,2 The overall cardiovascular mortality rate in patients undergoing chronic HD treatment is estimated to be approximately 30%, of which 10% are deaths because of myocardial infarction. 3 Recently, it has been shown that monocyte chemoattractant protein-1 (MCP-1) is a potent monocyte chemoattractant and largely responsible for the recruitment of monocytes/macrophages to the vessel wall in the early stage of atherogenesis. [4][5][6][7][8][9][10][11][12] In the clinical setting, it has been reported that the plasma concentrations of several cytokines and chemokines, including MCP-1, increased during long-term HD treatment. 13 However, there have been few studies of the relationship between the severity of human atherosclerosis and the serum concentration of MCP-1 in HD patients. 13,14 High-resolution ultrasound imaging is now a reliable means of directly examining and quantifying pre-clinical Circulation Journal Vol. 68, July 2004 atherosclerotic lesions in peripheral arteries. 15 This method is noninvasive and has high reproducibility. 16 Ultrasound measurements of intimal -medial thickness (IMT) in the carotid artery have been used as indicators of coronary atherosclerosis. 17 Tabara et al reported that the plasma concentration of MCP-1 was significantly associated with IMT in community-based subjects, aged 50 years or older and free from any cardiovascular complications. 18 In the present study, we measured IMT and investigated the effects of MCP-1 and other factors on the severity of IMT in HD patients. We also used immunohistochemistry to investigate the expression of MCP-1 in arterial tissue samples. Methods SubjectsAfter obtaining informed consent, 52 Japanese uremic patients undergoing chronic HD (29 men and 23 women; mean age, 56±10 years: HD group) and 20 age-matched control subjects (9 men and 11 women; mean age, 57±13 years: control group) were enrolled. In the patients undergoing chronic HD, the diagnosed kidney diseases were chronic glomerulonephritis in 47 patients and polycystic kidney disease in 5 patients. To avoid the influence of the cause of the disease, patients with diabetic nephropathy and hypertensive nephrosclerosis were excluded. Patients had been treated by HD 3 times a week for a mean duration of 10.1±7.4 years. The clinical and biochemical characteristics of the patients are summarized in Background Monocyte chemoattractant protein-1 (MCP-1), a potent chemoattractant for monocytes, plays an important role in the earliest events of atherogenesis. However, direct evidence of the effects of MCP-1 on atherosclerosis in chronic hemodialysis (HD) patients has not been reported. Methods and ResultsThe serum MCP-1 concentrations and the intimal -medial thickness (IMT) in the carotid arteries were measured in 42 non-diabetic chronic HD patients and 20 age-matched controls. The expression of MCP-1 was examined immunohistochemicall...

show abstract

“…Dialysis can reduce leukocyte-endothelial interactions and impair transmigration (Thylen et al 1997). In patients on hemodialysis with cuprophane or polysulfone membranes, a significantly higher serum level of MCP-1 is seen compared with healthy subjects both before and after the hemodialysis session, independent of the membrane used (Jacobson et al 2000;Thylen et al 2000). Biocompatibility of dialysis membranes probably plays an important role in determining leukocyte function in patients on hemodialysis (Himmelfarb et al 1991;Himmelfarb et al 1993;Hernandez et al 2004;Schindler et al 2006).…”

Section: Patients On Hemodialysismentioning

confidence: 99%